Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Creative Commons
Miguel Sogbe, Breianna Hummer, Jonathan G. Stine

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 8, 2024

Abstract Background MASLD is a leading reason for liver transplant waitlisting. The relationship between cardiorespiratory fitness (CRF) and fibrosis in patients with remains unclear. This study aims to provide further evidence supporting the CRF. Methods Subjects across various stages, including those cirrhosis awaiting transplantation from three U.S. centers, underwent cardiopulmonary exercise testing (CPX). We compared participants based on stage (F0-F1, F2-F3, F4) CPX parameters such as VO2peak, respiratory exchange ratio (RER), ventilatory efficiency (VE/VCO2), double product (DP) chronotropic incompetence (CI). Multivariable models were then built evaluate factors associated these parameters. Results Sixty-one subjects centers. F4 had lower VO2peak (11.8 mL/kg/min) F0-F1 (22.2 F2-F3 (22.9 mL/kg/min), p < 0.001. higher RER (median 1.25) (1.08) (1.05), = Similarly, exhibited VE/VCO2 36.5) (31) (30), Additionally, DP values 17,696) (25,460) (25,372), prevalence of CI (90%) (39%) (25%), both modeling confirmed advanced (F > 3) an independent predictor low Conclusions In patients, fibrosis, particularly cirrhosis, reduced CRF poorer hemodynamic performance during CPX. Prioritizing training earlier stages (F3) may prevent decline, which could hinder physical candidacy.

Language: Английский

Targeting Metabolism: Innovative Therapies for MASLD Unveiled DOI Open Access
Weixin Wang, Xin Gao, Wei Niu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4077 - 4077

Published: April 25, 2025

The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted critical role metabolism in disease’s pathophysiology. This innovative nomenclature signifies a shift from previous designation non-alcoholic fatty (NAFLD), emphasizing condition’s progressive nature. Simultaneously, MASLD become one most prevalent diseases worldwide, highlighting urgent need for research to elucidate its etiology and develop effective treatment strategies. review examines delineates revised definition MASLD, exploring epidemiology pathological changes occurring at various stages disease. Additionally, it identifies metabolically relevant targets within provides summary latest targeted drugs under development, including those clinical some preclinical stages. finishes with look ahead future therapy goal summarizing providing fresh ideas insights.

Language: Английский

Citations

0
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease DOI Creative Commons

Chen-yang Mu,

Sijie Wang,

Zenghan Wang

et al.

Annals of Hepatology, Journal Year: 2024, Volume and Issue: unknown, P. 101774 - 101774

Published: Dec. 1, 2024

Language: Английский

Citations

3
Effects of Tinospora cordifolia (giloy) on metabolic syndrome components: a mechanistic review DOI
M R Mansouri, Mohsen Imenshahidi, Maryam Rameshrad

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 28, 2024

Language: Английский

Citations

1
Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Creative Commons
Miguel Sogbe, Breianna Hummer, Jonathan G. Stine

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 8, 2024

Abstract Background MASLD is a leading reason for liver transplant waitlisting. The relationship between cardiorespiratory fitness (CRF) and fibrosis in patients with remains unclear. This study aims to provide further evidence supporting the CRF. Methods Subjects across various stages, including those cirrhosis awaiting transplantation from three U.S. centers, underwent cardiopulmonary exercise testing (CPX). We compared participants based on stage (F0-F1, F2-F3, F4) CPX parameters such as VO2peak, respiratory exchange ratio (RER), ventilatory efficiency (VE/VCO2), double product (DP) chronotropic incompetence (CI). Multivariable models were then built evaluate factors associated these parameters. Results Sixty-one subjects centers. F4 had lower VO2peak (11.8 mL/kg/min) F0-F1 (22.2 F2-F3 (22.9 mL/kg/min), p < 0.001. higher RER (median 1.25) (1.08) (1.05), = Similarly, exhibited VE/VCO2 36.5) (31) (30), Additionally, DP values 17,696) (25,460) (25,372), prevalence of CI (90%) (39%) (25%), both modeling confirmed advanced (F > 3) an independent predictor low Conclusions In patients, fibrosis, particularly cirrhosis, reduced CRF poorer hemodynamic performance during CPX. Prioritizing training earlier stages (F3) may prevent decline, which could hinder physical candidacy.

Language: Английский

Citations

0